MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA

这是一项多中心、随机、由制药公司发起的安慰剂对照试验，基质金属蛋白酶抑制剂(MMPI)Marimastat用于治疗已完成手术和放射治疗的多形性胶质母细胞瘤或胶质肉瘤住院患者。多个脑肿瘤中心将参与这项研究，患有恶性胶质瘤的患者将接受Marimastat(一种肿瘤细胞扩散抑制剂)或安慰剂(一种非活性治疗)治疗，这些患者在手术和放射治疗后复发。多个脑肿瘤中心将参与这项研究，患有脑肿瘤的患者将接受肿瘤细胞扩散抑制剂marimastat或安慰剂，这是一种针对手术和放疗后复发的恶性胶质瘤的非有效治疗方法。

This is a multi-center, randomized, drug company initiated, placebo controlled trial of marimastat, a matrix metalloproteinase inhibitor (MMPI), in the treatment of glioblastoma multiforme or gliosarcoma inpatients who have completed surgery and radiation therapy.Multiple brain tumor centers will participate in this study where patients with receive marimastat (an inhibitor of tumor cell spread) or placebo (an inactive treatment) for their malignant glial brain tumors that have returned after surgery and radiation. Multiple brain tumor centers will participate in this study where patients with receive marimastat an inhibitor of tumor cell spread or placebo, an inactive treatment for their malignant glial brain tumors that have returned after surgery and radiation.